Abstract:Background CHCHD2 was identified a novel cell migration-promoting gene, which could promote cell migration and altered cell adhesion when ectopically overexpressed in NIH3T3 fibroblasts, and it was identified as a protein necessary for OxPhos function as well. However, the clinic relevance of CHCHD2 expression in NSCLC remains unclear. Here we assumed that CHCHD2 expression would accompanies the expression of HIF-1α to response hypoxia in the occurrence of NSCLC. Methods In order to verify this hypothesis, correlations among the expression levels of CHCHD2 and HIF-1α were detected and analyzed in 209 pair cases of NSCLC. The expression and location of these molecules were assessed using Immunohistochemistry, immunohistofluorescence, qRT-PCR and western blotting. The differences and correlations of the expression of these two molecules with clinical pathological characteristics in NSCLC were statistically analyzed using Wilcoxon (W) text, Mann-Whitney U, Kruskal-Wallis H and cross-table tests. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of the expression of CHCHD2 and HIF-1α on the patients’ survival. Results Data showed that CHCHD2 and HIF-1α expression were higher in NSCLC than in normal tissues (all P = 0.000). CHCHD2 expression was significantly related with smoking, tumor size, differentiation degree, TNM Stage, lymph metastasis (all P< 0.05). The HIF-1α expression was significantly associated with smoking, tumor category, differentiation degree, TNM Stage, Lymph metastasis (all P< 0.05). There was a marked correlation of CHCHD2 and HIF-1α expression with histological type, differentiation and lymph metastasis of NSCLC (all P< 0.05, r s > 0.3). Immunohistofluorescence showed that there were co-localization phenomenon in cytoplasm and nucleus between CHCHD2 and HIF-1α expression. NSCLC patients with higher CHCHD2 and HIF-1α expression had a significantly worse prognosis than those with lower CHCHD2 and HIF-1α expression (all P = 0.0001; log-rank test). The multivariate analysis indicated that CHCHD2 expression was an independent prognostic factor in NSCLC (hazard ratio [HR], 0.492, P = 0.001). Conclusion Our results indicate that over-expression of CHCHD2 would promote the expression of HIF-1α to adapt the hypoxia microenviroment in NSCLC and CHCHD2 could serves as a prognostic biomarker in NSCLC.

Chd4 is Associated with Poor Prognosis of Non- Small Cell Lung Cancer Patients Through Promoting Tumor Cell Proliferation

CHD4 Mediates Proliferation and Migration of Non-Small Cell Lung Cancer Via the RhoA/ROCK Pathway by Regulating PHF5A

Putative Tumor-Suppressive Function of Krüppel-Like Factor 4 in Primary Lung Carcinoma

CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes

Long non-coding RNA OR3A4 is associated with poor prognosis of human non-small cell lung cancer and regulates cell proliferation via up-regulating SOX4.

CHD4 acts as a prognostic factor and drives radioresistance in HPV negative HNSCC

Loss of LIMCH1 Predicts Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics

Overexpression of CHD1L is Positively Associated with Metastasis of Lung Adenocarcinoma and Predicts Patients Poor Survival

USF1-CHCHD4 axis promotes lung adenocarcinoma progression partially via activating the MYC pathway

Overexpression of P4HA1 Associates with Poor Prognosis and Promotes Cell Proliferation and Metastasis of Lung Adenocarcinoma.

Low Expression of SCN4B Predicts Poor Prognosis in Non-Small Cell Lung Cancer

CHCHD2 is a Potential Prognostic Factor for NSCLC and is Associated with HIF-1a Expression.

CXCL1 As an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer

Non-SMC Condensin I Complex Subunit H (NCAPH), a Regulator of Cell Cycle, Predicts Poor Prognosis in Lung Adenocarcinoma Patients: a Study Mainly Based on TCGA and GEO Database

Expression and clinical significance of CHCHD2 in non-small cell lung cancer patients

High level of BRD4 promotes non-small cell lung cancer progression

The Prognostic Value Of C-X-C Chemokine Receptor 4 In Non-Small Cell Lung Cancer: A Meta-Analysis

CHD4 Promotes Acquired Chemoresistance and Tumor Progression by Activating the MEK/ERK Axis

CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma

Involvement of CHP2 in the Development of Non-Small Cell Lung Cancer and Patients' Poor Prognosis

CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis.